Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EpiCept AML Drug Gets “Exceptional Circumstances” Stamp From EU Regulators

This article was originally published in The Pink Sheet Daily

Executive Summary

Remission maintenance drug should receive formal EC approval within 67 days; new U.S. filing planned for 2009.

You may also be interested in...

Maxim Seeks Ceplene Development Partner After FDA Request For More Data

FDA indicates that approval of Ceplene for the treatment of acute myeloid leukemia would require confirmatory Phase III trial, Maxim says. The company previously withdrew an NDA for use of the oncologic in advanced malignant melanoma.

Pharmos Names Meer CFO

Pharmos has tapped former Schein VP James Meer as its chief financial officer.

QUOTED. 19 February 2020. Stephen Hahn.

The US FDA has abandoned all near-term plans to inspect Chinese manufacturing facilities in the wake of the coronavirus crisis. See what agency head Stephen Hahn said about it here.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts